Awarded Grants
Awarded Grants
Targeting the endocannabinoid system to treat epilepsy in Niemann Pick disease type C
Lola Ledesma
Centro Biologia Molecular Severo Ochoa
$40,140.00
Awardee: Lola Ledesma
Institution: Centro Biologia Molecular Severo Ochoa
Grant Amount: $40,140.00
Funding Period: February 1, 2024 - January 31, 2025
Summary:
Pharmacoresistent epilepsy is frequently found in NPC patients. This condition impact heavily in the quality of life of the patients and their families. Several studies have reported the ability of cannabinoids to reduce the frequency of seizures with a safe profile even in pediatric population. We have also shown the downregulation of the endocannabinoid system in the brain of an NPC mouse model and patient. We thus propose the enhancement of the endocannabinoid system as anti-epileptic treatment in the disease. We will assess the efficacy and safety of this strategy in a mouse model for NPC using oral administration of exogenous cannabinoids or of an inhibitor of the endocannabinoid degrading enzyme FAAH.
Leveraging proteostasis to improve Niemann-Pick C gene therapy
Mark Schultz
Regents of the University of Michigan
$50,010
Awardee: Mark Schultz
Institution: Regents of the University of Michigan
Grant Amount: $50,010
Funding Period: February 1, 2022 - January 31, 2023
Summary:
Niemann-Pick C is a genetically inherited disease caused by an abnormal accumulation of cholesterol. This cholesterol build-up commonly occurs due to a defect in a gene called NPC1. In Niemann-Pick C mouse models, adding back a fully functional NPC1 gene via gene therapy improves but does not fully correct the disease. Here we will leverage the information we have gained on protein folding to significantly increase the efficacy of Niemann-Pick C gene therapy.
Deciphering variants of unknown significance in Niemann Pick Type C
Evgueni Ivakine
Hospital for Sick Children
$47,630
Awardee: Evgueni Ivakine
Institution: Hospital for Sick Children
Award Amount: $47,630
Funding Period: February 1, 2021 - January 31, 2022
Summary:
As we enter an age where we understand more about genetic disease, we are beginning to regularly implement genome sequencing and personalized medicine in clinical practice. These efforts are hampered by a lack of knowledge about how mutations contribute to disease. This is particularly the case for diseases like Niemann-Pick disease type C (NPC), a rare genetic disease in which most patients present with a mutation that has not previously been reported. This leads to lengthy wait times between presentation and definitive diagnosis, as specialized laboratories are required to biochemically diagnose each potential patient. Through our work, we aim demonstrate a new method to quickly and easily create every possible mutation in each DNA base in a critical region of the the NPC1 gene using next-generation CRISPR-based gene editing technologies. Once we have generated a group of these mutant cells, we will perform a functional test to rapidly ascertain if each would likely lead to developing the disease or not. After identifying disease-causing mutations, we will apply a drug, currently undergoing clinical trials for NPC, to further classify the disease-causing mutations as responders or non-responders to this treatment.
Testing Niemann-Pick C proteostasis therapeutics on human iPSC derived neurons
Mark Schultz
Regents of the University of Michigan
$61,637
Awardee: Mark Schultz
Institution: Regents of the University of Michigan
Awarded Amount: $61,637
Repurposing FDA-approved drugs for Niemann Pick C Disease
Yamuna Krishnan
University of Chicago
$62,340
Awardee: Yamuna Krishnan
Institution: University of Chicago
Award Amount: $62,340
AAVrh.10-mediated Npc2 Gene transfer for the treatment of Npc2 Deficient Niemann-Pick disease
Dolan Sondhi
Weill Cornell Medicine
$49,645
Awardee: Dolan Sondhi
Institution: Weill Cornell Medicine
Award Amount: $49,645
Funding Period: January 1, 2018 - December 31, 2018
Targeting molecular chaperone HSP90 to treat NPC1 disease
Nina Pipalia
Weill Cornell Medical College
$49,645
Awardee: Nina Pipalia
Institution: Weill Cornell Medical College
Award Amount: $49,645
Funding Period: January 1, 2018 - December 31, 2018
Carboxyl lysosphingomyelin as a Biomarker for Diagnosis and Assessment of Treatment of NPC Disease
Xuntian Jiang
Washington University School of Medicine
$51,000
Awardee: Xuntian Jiang
Institution: Washington University School of Medicine
Award Amount: $51,000
Funding Period: January 1, 2017 - December 31, 2017
Impact on Niemann-Pick C disease of the cross-talk between the c-Abl and the TFEB signaling pathways
Silvana Zanlugo
Pontificia Universidad Católica de Chile
$51,000
Awardee: Silvana Zanlugo
Institution: Pontificia Universidad Católica de Chile
Award Amount: $51,000
Funding Period: January 1, 2017 - December 31, 2017
Characterization of NPC1-I1061T proteostasis machinery for development of NPC therapeutics
Andrew Lieberman
University of Michigan
53,500
Awardee: Andrew Lieberman
Institution: University of Michigan
Award Amount: $53,000
Funding Period: January 1, 2016 - December 31, 2016
Targeted AAV gene therapy for vertical supranuclear gaze palsy and dysphagia
Charles Vite
University of Pennsylvania
53,500
Awardee: Charles Vite
Institution: University of Pennsylvania
Award Amount: $53,500
Funding Period: January 1, 2016 - December 31, 2016
CNS gene therapy to restore NPC1 protein expression in cerebellar Purkinje cells and delay or prevent disease onset in feline Niemann-Pick type C1 (NPC1) disease.
Brittney Gurda
University of Pennsylvania, School of Veterinary Medicine
35,000
Awardee: Brittney Gurda
Institution: University of Pennsylvania, School of Veterinary Medicine
Award Amount: $35,000
Funding Period: January 1, 2015 - December 31, 2015
Dual targeting of defective lipid and metal pathways in Niemann-Pick type C disease: an in vitro pilot study
Ashley Bush
The Florey Institute of Neuroscience and Mental Health
50,000
Awardee: Ashley Bush
Institution: The Florey Institute of Neuroscience and Mental Health
Award Amount: $50,000
Funding Period: January 1, 2015 - December 31, 2015